FDA Lifts Clinical Hold on Aardvark Therapeutics Drug
Regulators have cleared Aardvark Therapeutics to resume the development program for its ARD-101 treatment.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Should pharmaceutical companies be required to prioritize safety testing over faster drug development timelines?
The FDA has officially lifted the clinical hold on the ARD-101 drug program after reviewing new safety data. Aardvark Therapeutics, based in San Diego, can now move forward with plans for future clinical trials.
Why it matters
This decision marks a critical milestone for the drug developer following an investigation into electrocardiogram changes. The clearance allows the company to realign on Phase 3 trial designs after previously pausing all dosing.
A safety study in healthy volunteers showed no cardiac events at dosages of 200 mg and 400 mg twice daily. The drug program was previously held due to observed electrocardiogram changes.
The players
Aardvark Therapeutics
A San Diego-based pharmaceutical company focused on developing therapies for metabolic and cardiovascular conditions.
Food and Drug Administration
The federal agency responsible for protecting public health by regulating pharmaceutical development and ensuring drug safety in the United States.
The details
The company conducted a series of internal assessments, including an in vitro cardiac sodium channel study and an ECG review, to address regulatory concerns. Additionally, Aardvark unblinded trial data accumulated from the HERO and OLE programs to confirm the safety profile of the treatment.
Timeline
February 27, 2026: Aardvark voluntarily paused dosing in the HERO and OLE trials.
May 2026: The FDA placed a formal clinical hold on the trials.
October 22, 2026: The FDA officially lifted the clinical hold on ARD-101.
October 23, 2026: Aardvark hosts a conference call and webcast to discuss trial data.
Health Landscape
This development follows the standard regulatory path defined by the FDA clinical hold process, which requires rigorous safety proof before proceeding. The resolution mirrors typical efforts by biotech firms to bridge safety gaps identified in early-stage cardiovascular testing.
For patients awaiting new treatment options, this update serves as a procedural step toward potential future availability. It confirms that the manufacturer is working directly with regulators to ensure therapy safety before continuing clinical research.
The takeaway
The lifting of the hold confirms that current safety data has met federal standards for continued study. Stakeholders should monitor upcoming design announcements to understand how trial requirements for future patients have evolved.
What happens next
Aardvark Therapeutics is scheduled to host a webcast on October 23, 2026, to discuss the findings from the terminated HERO and OLE trial data.
Further reading
Learn more about advancements in Heart Disease research.
Live Poll
Should pharmaceutical companies be required to prioritize safety testing over faster drug development timelines?
